Home / Psoriasis / 60 percent risk of alcohol-related death in psoriasis

60 percent risk of alcohol-related death in psoriasis

A population-based study of 55,537 psoriasis patients finds that these patients have a 60 percent greater risk of dying from alcohol-related causes as compared to a comparable group of non-psoriasis patients.

This may explain the premature mortality gap in this group of patients who have been known to have an increased risk of premature mortality, say the authors of the study which appears in the December issue of JAMA Dermatology.

Led by Darren Ashcroft, Ph.D., of the University of Manchester, the authors suggest that physicians consider incorporating routine alcohol screening into medical exams as well as the identification of alcohol consumption, treatment for alcohol misuse and use of the Alcohol Use Disorders Identification Test (AUDIT-C) in primary and secondary care settings.

“People diagnosed with psoriasis had a greater risk of dying, on average 3 years younger, due to alcohol-related causes, compared with the general population. Moreover, although there was no evidence of a variation in relative risk by sex, women with psoriasis died of alcohol-related causes at considerably younger age (approximately 5 years) than women without psoriasis who died from these causes,” the authors wrote.

Only two previous studies — published 20 years ago — have explored the possibility of alcohol-related mortalities in psoriasis patients.


The study included 55,537 adult psoriasis patients who were compared to 854,314 non-psoriasis patients. The patient pool was derived from electronic health records. The average age of the patients was 47 and 45 percent were men. It included 4.4 years of follow-up. The alcohol-related morality rate was 4.8 per 10,000-person years compared to 2.5 per 10,000-persons years for the comparison group.

Full Text

About Dr. J. Kim

Dr Kim developed (and is continuing to develop) dermatology research news as we way from dermatologists to stay on top of the latest advances in the field of dermatology.

Check Also

A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-1)

Study Description Go to  Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Brief Summary: The purpose of this study is to evaluate the efficacy and safety of mirikizumab in participants with moderate to severe plaque psoriasis. Condition or disease Intervention/treatment Phase Psoriasis Drug: Mirikizumab Drug: Placebo Phase 3 …

Leave a Reply

Your email address will not be published. Required fields are marked *